Insulet Corporation (PODD) stock is perceived attractive for investment, as shares have been recently bought by several investors such as Raleigh Capital Management, Virtu Financial, State of Tennessee Treasury Department, and Bridgewater Associates. Major **insider selling** has also been noted, with executives and directors like Timothy Scannell selling a considerable number of shares. Despite these activities, five-years returns for shareholders have been satisfactory, with strong earnings growth observed. Insulet recently presented robust full year and Q4 2023 **financial results**, with their Q1 2024 revenue view raised, following earnings that exceeded expectations. This growth is partially credited to the success of their **Omnipod® 5 Automated Insulin Delivery System** amongst other progress in their product pipeline. Several stock analysts remain confident in Insulet's performance, with some projecting possible recovery of its pre-inflation shock highs of $300. In the midst of these developments, Insulet Appointed Ana Maria Chadwick as CFO and announced its presentation at the upcoming Jefferies Global Healthcare Conference.
Insulet Corporation PODD News Analytics from Thu, 24 Aug 2023 07:00:00 GMT to Sun, 16 Jun 2024 16:07:08 GMT -
Rating 4
- Innovation 8
- Information 7
- Rumor -3
